AtriCure (ATRC) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
AtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company Following 2Q Beat
July 28, 2017 8:07 AM EDTNeedham & Company raised its price target on AtriCure Inc. (NASDAQ: ATRC) to $26.00 (from $25.00) while maintaining a Buy rating following the company's 2Q. Revenue was $45.2M vs. consensus of $44.2M, EBITDA was ($0.4M) vs. consensus of ($1.9M), and EPS was ($0.21) vs. consensus of ($0.26).
For... More
